Wiestner A. BCR pathway inhibition as therapy for chronic lymphocytic leukemia and lymphoplasmacytic lymphoma. Hematology Am Soc Hematol Educ Progam 2014;2014(1):125-134;
Advani RH, et al. Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies. J Clin Oncol 2013;31(1):88-94;
Nisitani S, et al. Posttranscriptional regulation of Bruton’s tyrosine kinase expression in antigen receptor-stimulated splenic B cells. Proc Natl Acad Sci USA 2000;97(6):2737-2742;
Chavez J, et al. Ibrutinib: an evidence-based review of its potential in the treatment of advanced chronic lymphocytic leukemia. Core Evid 2013;8:37-45.
CP-179661 - September 2020
Janssen-Cilag NV 2021. This site is published by Janssen-Cilag NV which is solely responsible for its content. It is intended for Healthcare professionals in Belgium and Luxembourg.